Ranitidine: Difference between revisions
Line 11: | Line 11: | ||
==Special Populations== | ==Special Populations== | ||
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: | *[[Drug Ratings in Pregnancy|Pregnancy Rating]]: B | ||
*Lactation: | *Lactation: Probably Safe | ||
*Renal Dosing | *Renal Dosing | ||
**Adult | **Adult: CrCl < 50: 150 mg Qday; CrCl < 10: 75 -150 mg Qday; HD: give dose after dialysis | ||
**Pediatric | **Pediatric: CrCl < 10-50: decrease dose 50%; CrCl< 10: decrease dose 75%; HD: Give dose after dialysis | ||
*Hepatic Dosing | *Hepatic Dosing | ||
**Adult | **Adult: Not defined | ||
**Pediatric | **Pediatric: not defined | ||
==Contraindications== | ==Contraindications== |
Revision as of 20:02, 28 March 2015
General
- Type: H2 Blocker
- Dosage Forms: 75, 150, 300
- Common Trade Names: Zantac
Adult Dosing
GERD: 150 mg PO BID
Pediatric Dosing
GERD: 5-10 mg/kg/day PO BID
Special Populations
- Pregnancy Rating: B
- Lactation: Probably Safe
- Renal Dosing
- Adult: CrCl < 50: 150 mg Qday; CrCl < 10: 75 -150 mg Qday; HD: give dose after dialysis
- Pediatric: CrCl < 10-50: decrease dose 50%; CrCl< 10: decrease dose 75%; HD: Give dose after dialysis
- Hepatic Dosing
- Adult: Not defined
- Pediatric: not defined
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
Common
Pharmacology
- Half-life:
- Metabolism:
- Excretion:
- Mechanism of Action: